Richard Saynor, CEO of Swiss pharmaceutical company Sandoz, stated in an interview with CNBC that no company would systematically continue to supply products at significant losses, thus manufacturers will face the choice of raising prices or ceasing supply. Donald Trump said in July that imported generic drugs could face a 100% tariff starting in 2028, potentially rising to 200% a year later, to encourage pharmaceutical companies to shift production to the United States.